What happened
On October 17, 2026, the board of Granules India approved the acquisition of 100% of Senn Chemicals AG, a Switzerland-based contract development and manufacturing organization (CDMO), for ₹192.5 crore (CHF 20 million). The board also approved the incorporation of a wholly owned subsidiary in India to support the acquisition and operations of Senn Chemicals, with an authorized share capital of ₹500 crore and paid-up share capital of ₹200 crore, subject to approval by India's Ministry of Corporate Affairs.
What is Senn Chemicals AG?
Senn Chemicals is a Swiss CDMO specializing in peptide synthesis — specifically liquid-phase peptide synthesis (LPPS) and solid-phase peptide synthesis (SPPS). A CDMO is a company that pharmaceutical firms hire to develop and manufacture drug compounds on their behalf, handling everything from early process research through commercial-scale production.
Peptides are short chains of amino acids. They sit between small-molecule drugs and complex biologics: easier to design with high specificity than traditional pills, and far simpler to manufacture than antibodies. That middle ground is exactly why the peptide market is growing fast. Senn provides contract research, development, and manufacturing services to clients in the pharmaceutical, cosmetics, and theragnostic (combined diagnostic-and-therapeutic) industries.
Company-reported figures cited in the announcement put Senn's revenue at CHF 26.9 million in calendar year 2023, with projected revenue of CHF 19.6 million in 2024. The purchase price of CHF 20 million therefore values the company at roughly one times its projected revenue — a valuation that reflects Granules paying for capability and R&D infrastructure rather than for a fast-growing revenue stream.
The GLP-1 connection
The strategic centerpiece of the deal is diabetes and obesity treatment. GLP-1 receptor agonists — the class of peptide drugs behind the global weight-loss drug boom — are among the fastest-growing therapeutic categories in the world. Granules and Senn have already been collaborating on the development of two GLP-1-based active pharmaceutical ingredients (APIs), with further peptide-based APIs planned through Senn's R&D expertise.
Granules' Chairman and Managing Director, Krishna Prasad Chigurupati, framed the acquisition as part of the company's push into next-generation therapeutics, positioning Granules as a player in complex and specialized medicines. Senn's Chairman, Rico Wiedenbruch, pointed to Granules' scale, operational efficiency, and global reach as the reason Senn chose the partnership.
The classic playbook: Swiss science, Indian scale
This deal follows a well-worn and proven template: pair European specialty R&D with Indian manufacturing scale. Senn contributes specialized peptide know-how, established customer relationships, and R&D infrastructure. Granules contributes cost-efficient, large-scale manufacturing — the ability to make complex molecules at volumes and prices the global market will bear.
For the pharmaceutical industry, the timing is significant. Many blockbuster GLP-1 drugs face patent expirations over the coming years, and generic and biosimilar manufacturers are racing to build peptide manufacturing capacity now so they are ready when those cliffs arrive. A low-cost, high-quality peptide supply chain based in India is exactly what global buyers will need.
Context: Granules' own numbers
The acquisition comes as Granules reported softer recent results: a company-reported 6.41% decline in consolidated net profit to ₹117.60 crore for Q3 FY25, alongside a 1.55% decline in total revenue to ₹1,137.70 crore compared to Q3 FY24. The Senn deal signals that management is investing in higher-margin, specialized therapeutic areas to diversify beyond its legacy generics business.
Why it matters for founders
For founders in biotech and life-sciences services, the Granules-Senn deal illustrates what acquirers actually pay for: differentiated technical capability with a path to scale. Senn was valued at roughly one times projected revenue — a reminder that small CDMOs get acquired for expertise, client relationships, and pipeline optionality, not just financials. If you are building a niche CDMO or drug-delivery platform, the GLP-1 ecosystem and the coming patent cliffs are creating a seller's market for specialized capacity.
Why it matters for investors
The deal is a datapoint in a larger thesis: the GLP-1 supply chain is becoming an investable theme beyond the drugmakers themselves. Peptide synthesis capacity, fill-finish infrastructure, and API manufacturers are the picks-and-shovels plays of the obesity-drug era. Small-to-mid-cap Indian pharma companies buying Western specialty assets at reasonable valuations — and then scaling them — is a repeatable value-creation model worth watching.
Angeled.com connects founders building in biotech, pharma services, and healthtech with investors who understand the space.
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



